Literature DB >> 16845248

Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients.

Deniz Agirbasli1, Mehmet Agirbasli, Scott M Williams, John A Phillips.   

Abstract

BACKGROUND: Genetic factors play a role in the onset of coronary artery disease. The objective of our study is to evaluate the single locus and combined effects of three different genetic polymorphisms (methylenetetrahydrofolate reductase C677T polymorphism, plasminogen activator inhibitor 4G/5G polymorphism, and endothelial nitric oxide synthase 3-27 base pairs repeat polymorphism) on the presence and extent of coronary artery disease in patients with early-onset coronary artery disease.
MATERIALS AND METHODS: DNA samples were obtained from 102 consecutive patients with symptoms resulting from early-onset coronary artery disease documented by coronary angiography. The severity of coronary artery disease in patients was stratified into three groups as one, two, or three-vessel coronary artery disease. The control group was selected from older subjects with a recent and negative cardiac work-up. Information on standard risk factors was collected. Multifactor dimensionality reduction analysis was performed to seek a model of coronary artery disease based on these three genetic polymorphisms.
RESULTS: Single-locus effects of the three polymorphisms were not significantly related to the presence or severity of coronary artery disease. When gene-gene interactions were studied, however, the severity of disease was related to the frequency of high-risk alleles, yet advanced analysis did not detect a significant genetic model for coronary artery disease in these patients based on these three genetic polymorphisms.
CONCLUSION: These three genetic polymorphisms are susceptibility loci and genotypes of these genes are neither necessary nor sufficient for the coronary artery disease to occur, but coexistence of high-risk alleles may increase the severity of coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845248     DOI: 10.1097/00019501-200608000-00003

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  6 in total

1.  Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.

Authors:  Mehmet Agirbasli; Mesut Eren; Songul Yasar; Kenan Delil; Fatih Goktay; Ebru Toksoy Oner; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

2.  Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.

Authors:  Mehmet Agirbasli; Mesut Eren; Fatih Eren; Sheila B Murphy; Zehra A Serdar; Dilek Seckin; Tuba Zara; M Cem Mat; Cuyan Demirkesen; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

3.  Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis.

Authors:  Huifeng Zhang; Pingshuan Dong; Xuming Yang; Zhenghao Liu
Journal:  Int J Clin Exp Med       Date:  2014-10-15

4.  Lack of Association between Glutathione S-Transferase-M1, -T1, and -P1 Polymorphisms and Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.

Authors:  Young-Min Park; Heon-Jeong Lee; Seung-Gul Kang; Jung-Eun Choi; Jae-Hyuck Cho; Leen Kim
Journal:  Psychiatry Investig       Date:  2010-05-12       Impact factor: 2.505

5.  Endothelial nitric oxide synthase (eNOS) 4b/a gene polymorphisms and coronary artery disease: evidence from a meta-analysis.

Authors:  Yujiao Yang; Kang Du; Zhengxia Liu; Xiang Lu
Journal:  Int J Mol Sci       Date:  2014-05-07       Impact factor: 5.923

Review 6.  Association of endothelial nitric oxide synthase gene polymorphisms with coronary artery disease: an updated meta-analysis and systematic review.

Authors:  Himanshu Rai; Farah Parveen; Sudeep Kumar; Aditya Kapoor; Nakul Sinha
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.